CSWYF's ROE % is ranked better than 72.01% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs CSWYF: 12.30
China Shineway Pharmaceutical Group (OTCPK:CSWYF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
China Shineway Pharmaceutical Group ROE % Related Terms
China Shineway Pharmaceutical Group ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's ROE % distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
China Shineway Pharmaceutical Group (CSWYF) has a ROE % of 8.53% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on China Shineway Pharmaceutical Group and its competitors. This is 15% below median its historical median of 10.05. Over the past decade, China Shineway Pharmaceutical Group's ROE % has ranged from 5.26 to 14.31. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #262 out of 936 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is China Shineway Pharmaceutical Group's ROE % too high?
China Shineway Pharmaceutical Group's current ROE % of 8.53% is 15% below median its 10-year median of 10.05. Over the past 10 years, this metric has ranged from a low of 5.26 to a high of 14.31. The Drug Manufacturers industry median ROE % is 5.87. China Shineway Pharmaceutical Group's value of 8.53% is 45.4% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #262 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #262 out of 936 companies for ROE %. This puts China Shineway Pharmaceutical Group in the upper half of its industry. The industry median ROE % is 5.87. China Shineway Pharmaceutical Group's value of 8.53% is 45.4% above this benchmark. Historically, China Shineway Pharmaceutical Group's own ROE % has ranged from 5.26 to 14.31 over the past decade. While the company's 10-year median is 10.05 vs. the industry median of 5.87, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current ROE % of 8.53% is 45.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current ROE % is 8.53%, which is 15% below median its own 10-year median of 10.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYF) has a current ROE % of 8.53%. The stock's GF Value™ is $0.88, compared to a current price of $1.00 — trading 14.1% above its estimated fair value. The current ROE % is 8.53%, which is 15% below median its 10-year median of 10.05 and 45.4% above the Drug Manufacturers industry median of 5.87. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYF), the current ROE % is 8.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYF) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.00 is trading 14.1% above its estimated GF Value™ of $0.88.
Key valuation signals for CSWYF:
ROE %: 8.53% (15% below median its 10-year median of 10.05)
GF Value™: $0.88 vs. price of $1.00 (14.1% above fair value)
Industry Position: 45.4% above the Drug Manufacturers median (#262 of 936)
No single metric tells the full story. See the CSWYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYF has been successfully added to your 
